Donald Grimm Named New Hybritech President

Hybritech Inc., a subsidiary of Eli Lilly and Co., announced that Donald W. Grimm has been named president and chief executive officer of the monoclonal antibody-based biotechnology company, replacing Stephen A. Stitle, who had been president on an interim basis. Stitle will continue as president of Lilly’s monoclonal diagnostics and therapeutics division.

Grimm previously held various management sales and marketing positions in Lilly’s pharmaceutical division. He will relocate to San Diego from Los Angeles.